Status:
COMPLETED
Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
Lead Sponsor:
Novartis Pharmaceuticals
Collaborating Sponsors:
University of Athens
Conditions:
Prostate Cancer
Eligibility:
MALE
18-80 years
Phase:
PHASE4
Brief Summary
The objective of this study is to assess the effect Of zoledronic acid on circulating and bone marrow-residing prostate cancer cells in patients with clinically localized prostate cancer
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Prostate cancer
- Radical prostatectomy or external beam irradiation therapy within 6 months before study entry.
- No bone metastases according to bone scan
- Exclusion Criteria
- Metastatic prostate cancer
- Hormone ablation therapy for more than 3 months before/after radical prostatectomy and external beam irradiation therapy
- Treatment with bisphosphonates or other drugs known to affect the skeleton within the past year.
- Other protocol-defined inclusion / exclusion criteria may apply.
Exclusion
Key Trial Info
Start Date :
September 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2009
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00219271
Start Date
September 1 2003
End Date
September 1 2009
Last Update
May 31 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Athens, Greece